A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: Implications for residual disease detection

Leukemia

Volumn 13, Issue 4, 1999, Pages 558-567

  Weir, E G ^a   Cowan, K ^a   LeBeau, P ^a   Borowitz, M J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Acute lymphoblastic leukemia; B cell precursors; Minimal residual disease; Multiparameter flow cytometry

Indexed keywords

ANTIBODY; CD19 ANTIGEN; CD20 ANTIGEN; CD45 ANTIGEN; CD9 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0032957090     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401364     Document Type: Article

References (53)

1. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera CK, Sandlund JT, Pui CH, Campana D. Immunologic detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet 1998; 351: 550-554.
2. Pui CH. Childhood leukemias. New Engt J Med 1995; 332: 1618-1630.
3. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia: 30 years experience at St Judes Children's Research Hospital. New Engl J Med 1993; 329: 1289-1295.
4. Poplack DG, Reaman GM. Acute lymphoblastic leukemia in childhood. Pediatr Clin N Am 1988; 35: 903-932.
5. Cave H, Guidai C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, Elion J, Vilmer E, Crandchamp B. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T cell receptor genes. Blood 1994; 83: 1892-1902.
6. Wright JJ, Poplack DG, Bakhshi A, Reaman G, Cole D, Jensen JP, Korsmeyer SJ. Gene rearrangements as markers of clonal variation and minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1987; 5: 735-741.
7. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Weite K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
8. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, Crist WM, Pui CH. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292-1295.
9. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappel R, Hammond D, Bleyer WA. Cytoreduction and prognosis in acute lymphoblastic leukemia: the importance of early marrow response. J Clin Oncol 1996; 14: 389-398.
10. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurements of residual leukemia during remission in childhood acute lymphoblastic leukemia. New Engl J Med 1997; 336: 317-323.
11. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood 1995; 85: 1416-1434.
12. Srisco MJ, Condon J, Hughes E, Neoh SH, Nicholson I, Sykes PJ, Tauro C, Ekert H, Waters K, Toogood I, Seshadri R, Morley A and the Australian and New Zealand Children's Cancer Study Group. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Leukemia 1993; 7: 1514-1520.
13. Brisco MJ, Condon J, Sykes PJ, Neoh SH, Morley AA. Detection and quantitation of neoplastic cells in acute lymphoblastic leukemia by use of the polymerase chain reaction. Br J Haematol 1991; 79: 211-217.
14. Wu N-H, Lu S-C, Zhu P, Peng Y-Y. Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy. Pediatr Hematol Oncol 1996; 13: 257-263.
15. Steward CS, Goulden NJ, Katz F, Baines D, Martin P, Langlands K, Potter M, Chessells J, Oakbill A. A polymerase chain reaction of the stability of Ig heavy chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994; 83: 1355-1362.
16. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera C. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. New Engl J Med 1990; 323: 448-452.
17. Neale GAM, Menarguez J, Kitchingman GR, Fitzgerald TJ, Koelher M, Mirro J, Goorha RM. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 1991; 78: 739-745.
18. Yokota S, Hansen-Hagge TE, Ludwig W-D, Reiter A, Raghavachar A, Kleihauer E, Bartram C. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991; 77: 331-339.
19. Biondi A, Yokota S, Hansen-Hagge T, Rossi V, Giudici G, Maglia O, Basso C, Tell C, Masera C, Bartram CR. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992; 6: 282-288.
20. Wasserman R, Galili N, Ito Y, Silber J, Reichard B, Shane S, Wormer RB, Lange B, Rovera G. Residual disease at the end of the induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 1879-1885.
21. Ito Y, Wasserman R, Galili N, Reichard BA, Shane S, Lange B, Rovera G. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 546-550.
22. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martiat P. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993; 82: 1618-1625.
23. Kitchingman GR. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia 1994; 8: 395-402.
24. Brisco MJ, Condon J, Hughes E, Neoh S, Sykes P, Seshadri R, Toogood I, Waters K, Tauro C, Ekert H, Morley A. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
25. Seriu T, Yokota S, Nakao M, Misawa S, Takaue Y, Koizumi S, Kawai S, Fujimoto T. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. Leukemia 1995; 9: 615-623.
26. Jacquy C, Delepaut B, Van Daele S, Vaerman J, Zenebergh A, Brichard B, Vermylen C, Cornu G, Martiat P. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997; 98: 140-146.
27. Dibenedetto SP, Lo Nigro L, Pine Mayer S, Rovera G, Schilliro G. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997; 90: 1226-1232.
28. Cayuela J-M, Baruchel A, Orange C, Madani A, Auclerc MF, Daniel MT, Schaison G, Sigaux F. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996; 88: 302-308.
29. Cimino G, Elia L, Rivolta A, Rapanotti MC, Rossi V, Alimena G, Annino L, Canaani E, Lo Coco F, Biondi A. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol 1996; 92: 659-664.
30. Privitera E, Rivolta A, Ronchetti D, Mosna G, Giudici G, Biodi A. Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. Br J Haematol 1996; 92: 653-658.
31. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, Cleary ML. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1998; 91: 1021-1028.
32. Vervoordeldonk SF, Merle PA, Behrendt H, Steenbergen EJ, Van Leeuwen EF, Van den Berg H, Von dem Borne AE, Van der Schoot C and Slaper-Cortenbach IC. Triple immunofluorescence staining for prediction of relapse in childhood B acute lymphoblastic leukemia. Br J Haematol 1996; 92: 922-928.
33. Wormann B. Implications of detection of minimal residual disease. Curr Opin Oncol 1993; 5: 3-12.
34. Wormann B, Safford M, Konemann S, Buchner T, Hiddeman W, Terstappen LW. Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry. Rec Results Cancer Res 1993; 131: 185-196.
35. Sievers EL, Loken MR. Detection of minimal residual disease in acute myelogenous leukemia. J Pediatr Hematol Oncol 1995; 17: 123-133.
36. Greisinger F, Piro-Noack M, Falk M. High predictive value of relapse by three-color flow cytometric detection of leukemia-associated immunophenotype (LAIP) positive cells in acute lymphoblastic leukemia (ALL). Blood 1996; 88: (Suppl 1) 478a.
37. Drach J, Drach D, Glassl H, Gattringer C, Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13: 893-901.
38. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, O'Brien MC, Baron S, Deisseroth AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
39. Lavabre-Bertrand T, Janossy G, Ivory K, Peters R, Seeker-Walker L, Porwit-MacDonald A. Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression. Cytometry 1994; 18: 209-217.
40. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163-171.
41. Campana D. Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 1994; 18: 68-74.
42. Macedo A, Orfao A, Gonzalez M, Vidriales M, Lopez-Berges M, Martinez A, San Miguel JF. Immunologic detection of blast cell populations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995; 9: 993-998.
43. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 1987; 70: 1316-1324.
44. Ryan DH, Chapple CW, Kossover SA, Sandberg AA, Cohen HJ. Phenotypic differences and similarities between CALLA-positcve acute lymphoblastic leukemia cells and normal marrow CALLA-positive B cell precursors. Blood 1987; 70: 814-821.
45. Dworzak M, Fritsch G, Fleischer C, Printz D, Froschl D, Buchinger P, Mann G, Gadner H. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia 1997; 11: 1266-1273.
46. Vandersteenhoven AM, Williams JE, Borowitz MJ. Marrow B-cell precursors are increased in lymphomas or systemic diseases associated with B-cell dysfunction. Am J Clin Pathol 1993; 100: 60-66.
47. Lavabre-Bertrand T, George F, Brunet C, Sampol J. Quantitative immune phenotyping: a new dimension for the monitoring of haemopoietic malignancies. Nouv Rev Fr Hematol 1994; 36: 373-382.
48. Farahat N, Lens D, Zomas A, Morilla R, Matutes E, Catovsky D. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors. Br J Haematol 1995; 91: 640-646.
49. Shah VO, Civin CI, Loken MR. Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. J Immunol 1988; 140: 1861-1867.
50. Lavabre-Bertrand T, Duperray C, Brunet C, Poncelet P, Exbrayat C, Bourquard C, Lavabre-Bertrand C, Brochier J, Navarro M, Janossy G. Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias. Leukemia 1994; 8: 402-408.
51. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Cole Sinclair MF, Chim JS, Cannell P, Seeker-Walker LM, Mehta AB, Prentice HG, Hoffbrand AV. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukemia reveals differences in treatment response. Leukemia 1997; 11: 1732-1741.
52. Cave H, ten Bosch JVDW, Suciu S, Guidai C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New Engl J Med 1998; 339: 591-598.
53. Orfao A, Ciudad J, Lopez-Berges MC, Lopez A, Vidriales B, Caballero M, Valverde B, Gonzalez M, San Miguel J. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) by flow cytometry. Leuk Lymphoma 1994; 13: 87-90.